ATE390425T1 - Xanthin-phosphodiesterase-v-hemmer polymorphe - Google Patents

Xanthin-phosphodiesterase-v-hemmer polymorphe

Info

Publication number: ATE390425T1
Authority: AT; Austria
Prior art keywords: polymorphos; inhibitor; xanthine phosphodiesterase; phosphodiesterase; xanthine
Prior art date: 2002-05-31

Application number

AT03756248T

Other languages

English (en)

Inventor

Vilas Dahanukar

Hoa Nguyen

Cecilia Orr

Fucheng Zhang

Ilia Zavialov

Kevin Klopfer

Jeffrey Skell

Albert Buchholz

Craig Boyle

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-31

Filing date

2003-05-30

Publication date

2008-04-15

2003-05-30 Application filed by Schering Corp filed Critical Schering Corp

2008-04-15 Application granted granted Critical

2008-04-15 Publication of ATE390425T1 publication Critical patent/ATE390425T1/de

Links

LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title 2
239000002590 phosphodiesterase V inhibitor Substances 0.000 title 1
229940075420 xanthine Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT03756248T 2002-05-31 2003-05-30 Xanthin-phosphodiesterase-v-hemmer polymorphe ATE390425T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US38448402P	2002-05-31	2002-05-31

Publications (1)

Publication Number	Publication Date
ATE390425T1 true ATE390425T1 (de)	2008-04-15

Family

ID=29712042

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03756248T ATE390425T1 (de)	2002-05-31	2003-05-30	Xanthin-phosphodiesterase-v-hemmer polymorphe

Country Status (15)

Country	Link
US (1)	US7192962B2 (de)
EP (1)	EP1509524B1 (de)
JP (1)	JP2005529933A (de)
CN (1)	CN100384844C (de)
AR (1)	AR040233A1 (de)
AT (1)	ATE390425T1 (de)
AU (1)	AU2003249658A1 (de)
CA (1)	CA2486174A1 (de)
DE (1)	DE60319980T2 (de)
ES (1)	ES2299720T3 (de)
MX (1)	MXPA04011865A (de)
PE (1)	PE20040538A1 (de)
TW (1)	TW200404802A (de)
WO (1)	WO2003101991A1 (de)
ZA (1)	ZA200409644B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
CN100522174C (zh) *	2001-03-27	2009-08-05	大日本住友制药株式会社	结晶异唑衍生物及其药物制剂
CA2483923A1 (en) *	2002-05-31	2003-12-11	Schering Corporation	Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
WO2005012303A1 (en) *	2003-07-31	2005-02-10	Schering Corporation	Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
WO2005051368A2 (en) *	2003-11-21	2005-06-09	Schering Corporation	Phosphodiesterase v inhibitor formulations
CA2568640C (en)	2004-06-04	2011-08-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
WO2006055573A2 (en) *	2004-11-18	2006-05-26	Schering Corporation	Methods of using pde v inhibitors for the treatment of congestive heart failure
US20070004745A1 (en) *	2005-03-25	2007-01-04	Schering-Plough Corporation	Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
SI1883397T1 (sl) *	2005-05-17	2010-04-30	Actelion Pharmaceuticals Ltd	Disperzibilne tablete bosertana
US20070031349A1 (en) *	2005-06-23	2007-02-08	David Monteith	Rapidly absorbing oral formulations of PDE 5 inhibitors
WO2007070426A2 (en) *	2005-12-09	2007-06-21	Mayo Foundation For Medical Education And Research	Sexual dysfunction
WO2008139574A1 (ja) *	2007-04-27	2008-11-20	Ajinomoto Co., Inc.	ラクタム化合物の結晶形およびその製造方法
JP7291077B2 (ja)	2016-12-16	2023-06-14	ヤンセンファーマシューティカエヌ．ベー．	Ｊａｋファミリーのキナーゼの低分子阻害物質
JOP20190144A1 (ar)	2016-12-16	2019-06-16	Janssen Pharmaceutica Nv	إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh)	2018-06-15	2020-05-01	比利時商健生藥品公司	Ｊａｋ激酶家族之小分子抑制劑
AU2022233254A1 (en)	2021-03-11	2023-10-26	Janssen Pharmaceutica Nv	Lorpucitinib for use in the treatment of jak mediated disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9301192D0 (en)	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
TW526195B (en) *	1997-06-10	2003-04-01	Novartis Ag	Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
TR199903299T2 (xx) *	1997-07-02	2000-07-21	Merck & Co., Inc.	Ta�ikinin resept�r antagonisti 2-(R)-(1-(R)- (3,5-Bis(triflorometil) Fenil)Etoksi-3-(S)- (4-Floro)Fenil-4- (3-5(-okso-1H,4H-1,2,4-Triazolo) metilmorfolin'in polimorfik formu.
JP4441746B2 (ja) *	1997-08-27	2010-03-31	ノバルティスアーゲー	ジシクラニル多形および水和物ならびにそれらの調製
MA24682A1 (fr) *	1997-10-23	1999-07-01	Smithkline Beecham Corp	Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
FR2779726B1 (fr) *	1998-06-15	2001-05-18	Sanofi Sa	Forme polymorphe de l'hydrogenosulfate de clopidogrel
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
CA2483923A1 (en) *	2002-05-31	2003-12-11	Schering Corporation	Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof

2003
- 2003-05-30 US US10/449,650 patent/US7192962B2/en not_active Expired - Fee Related
- 2003-05-30 AU AU2003249658A patent/AU2003249658A1/en not_active Abandoned
- 2003-05-30 MX MXPA04011865A patent/MXPA04011865A/es active IP Right Grant
- 2003-05-30 EP EP03756248A patent/EP1509524B1/de not_active Expired - Lifetime
- 2003-05-30 AT AT03756248T patent/ATE390425T1/de not_active IP Right Cessation
- 2003-05-30 CA CA002486174A patent/CA2486174A1/en not_active Abandoned
- 2003-05-30 WO PCT/US2003/016890 patent/WO2003101991A1/en not_active Ceased
- 2003-05-30 DE DE60319980T patent/DE60319980T2/de not_active Expired - Lifetime
- 2003-05-30 PE PE2003000535A patent/PE20040538A1/es not_active Application Discontinuation
- 2003-05-30 CN CNB038124564A patent/CN100384844C/zh not_active Expired - Fee Related
- 2003-05-30 AR ARP030101922A patent/AR040233A1/es unknown
- 2003-05-30 ES ES03756248T patent/ES2299720T3/es not_active Expired - Lifetime
- 2003-05-30 TW TW092114739A patent/TW200404802A/zh unknown
- 2003-05-30 JP JP2004509682A patent/JP2005529933A/ja active Pending
2004
- 2004-11-29 ZA ZA200409644A patent/ZA200409644B/en unknown

Also Published As

Publication number	Publication date
ZA200409644B (en)	2005-10-18
AR040233A1 (es)	2005-03-23
HK1068140A1 (en)	2005-04-22
JP2005529933A (ja)	2005-10-06
CN100384844C (zh)	2008-04-30
DE60319980T2 (de)	2009-04-16
US20030232845A1 (en)	2003-12-18
US7192962B2 (en)	2007-03-20
WO2003101991A1 (en)	2003-12-11
EP1509524B1 (de)	2008-03-26
DE60319980D1 (en)	2008-05-08
PE20040538A1 (es)	2004-08-30
TW200404802A (en)	2004-04-01
ES2299720T3 (es)	2008-06-01
CN1656097A (zh)	2005-08-17
MXPA04011865A (es)	2005-03-31
AU2003249658A1 (en)	2003-12-19
CA2486174A1 (en)	2003-12-11
EP1509524A1 (de)	2005-03-02

Legal Events

Date	Code	Title	Description
2008-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DK1319003T3 (da)	2009-09-28	Xanthin-phosphodiesterase V-inhibitorer
DE60304911D1 (de)	2006-06-08	Xanthin-Derivate als DPP-IV-Inhibitoren
ATE395349T1 (de)	2008-05-15	Polycyclische guanin phosphodiesterase inhibitoren
ATE505471T1 (de)	2011-04-15	Azaindol-kinaseinhibitoren
NO2014008I2 (no)	2014-04-08	Linagliptin
DK1487805T3 (da)	2012-10-15	Pyrimidinderivater
IS7599A (is)	2004-12-15	Heterósýklískir kínasatálmar
DE60329282D1 (de)	2009-10-29	Cyano-pyrrolidine als DPP-IV Inhibitoren
DK1549652T3 (da)	2009-02-23	Kondenserede azolpyrimidinderivater
IS7872A (is)	2005-05-30	Pýrrólópýrimidín afleiður
ATE452891T1 (de)	2010-01-15	Pyrimidopyrimidone als kinaseinhibitoren
ATE256127T1 (de)	2003-12-15	Betacarbolinderivate als phosphodiesterase- inhibitoren
DK1658291T3 (da)	2013-10-28	Substituerede 8-heteroaryl xanthiner
DE60319273D1 (de)	2008-04-03	Entzunderungsdüse
ATE529428T1 (de)	2011-11-15	Thioxanthinderivate als myeloperoxidaseinhibitoren
EP1546115A4 (de)	2010-08-04	Substituierte pyrimidine
NL1024643A1 (nl)	2004-05-03	Purineverbindingen en gebruik daarvan.
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
ATE460418T1 (de)	2010-03-15	Heterocyclocarboxamidderivate
DE60330372D1 (de)	2010-01-14	Indol-3-schwefelderivate
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
ATE438644T1 (de)	2009-08-15	Chinazolinderivate
ATE278690T1 (de)	2004-10-15	Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DE50300841D1 (de)	2005-09-01	Bohrfutter
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer